• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

5

CATEGORIES

  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

1
1
1
8

PUBLISHED

0
0
1
8

PRODUCT TYPE

8

Search "Renal Cell Carcinoma Cancer Drug Futures 2010" returned 8 results.

Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

'Kidney Cancer Drugs Market (Major Drugs: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Sutent (Sunitinib), Torisel (Temsirolimus), Votrient...

January 2015
FROM

Kidney Cancer Drugs - Global Business Strategic Report

This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on Kidney Cancer Drugs provides market analytics specifically for the "Renal Cell Carcinoma" (RCC) market,...

May 2012
FROM

Cancer Therapies - Global Strategic Business Report

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy The report provides...

October 2011
FROM

Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators Annual...

May 2012
FROM

Multiplexed Diagnostics 2010 Market Report

The multiplexed diagnostics market has grown rapidly and generated sales of approximately $2 4 billon in 2009, but is now balanced on multiple tipping points Will the FDA finally release the updated...

May 2011

Breast Cancer Drug Discoveries: What the Future Holds

In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies With a large unmet clinical need, further agents are required to increase survival and delay disease progression...

August 2011
FROM

Successes and Failures for Avastin (Bevacizumab) mean Mixed News for the Blockbuster Drug in the Oncology Therapeutics Market

Successes and Failures for Avastin (Bevacizumab) mean Mixed News for the Blockbuster Drug in the Oncology Therapeutics Market Summary Avastin (bevacizumab) is a vascular endothelial growth factor...

May 2011
FROM

High-Growth Diagnostic Testing Markets

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also...

November 2013
FROM
Loading Indicator

Our Clients

Innocent Drinks Ltd. Groupe Danone Cisco Systems, Inc. The World Bank Group Swarovski AG Owens Corning Corporation Swiss Reinsurance Company Ltd.